1470PFirst real life data on durvalumab after definitive concomitant chemoradiotherapy (cCRT) in unresectable stage (St) III non-small cell lung cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) temporary authorization of use (ATU)

Abstract Background Among pts with St III unresectable NSCLC, only 15% are alive at 5 years with the historical Standard of Care (SoC) of definitive cCRT. Durvalumab, a human monoclonal anti-PD-L1 antibody, demonstrated efficacy in PFS and OS and was approved in Europe on September 2018 for the trea...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser:	Avrillon, V, Bota Ouchlif, S, Merle, P, Pichon, E, Stancu, A T, Chouaid, C, Sire, C, Boudabous, H, Lagrange, A, Sabatini, M, Eberst, G, Boisselier, P, Gourion, A, Lion, A, Lahouegue, A, Belkhiria, K, de La Porte, I, Urbieta, M, Mornex, F, Girard, N
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!